学术会议:紧随研究趋势 洞察学术热点 进入>
产业会议:新技术,新领域,深入产业环节 进入>
举办会议及论坛超过百场 邀请海内外院士超过50名 教授PI专家授课超过1000名 总参会人数超过10万人
2019-11-04至2019-11-06
导航

特邀嘉宾Special Guest

Yufang Shi(时玉昉) 教授

苏州大学转化医学研究院,苏州大学附属第一医院

Yufang Shi(时玉昉) 教授

苏州大学转化医学研究院,苏州大学附属第一医院

国家特聘专家

苏州大学附属第一医院副院长

苏州大学转化医学研究院院长

放射医学与辐射防护国家重点实验室副主任

 

国家特聘专家,国家自然基金委杰出青年;国家973研究计划总体组成员;国家973重大研究计划生殖与发育专项召集人;国家973重大研究计划和国家重点研发计划首席科学家;国际细胞治疗学会间充质干细胞治疗分会专家组成员;1992年获加拿大阿尔伯塔大学免疫学博士学位;1995年在乔治·华盛顿大学建立独立实验室,2012年晋升为新泽西医科大学终身正教授和特聘大学教授;2008年至2014年担任中科院健康科学研究所教授,所长;于2014年7月加盟苏州大学,任转化医学研究院院长和特聘教授,同时任苏州大学附属第一医院副院长。

目前担任Cell Death and Disease杂志主编(Editor-in-Chief);Oncogene副主编(Associate Editor);Cell Death and Differentiation编审(Receiving Eidtor);Stem Cell Research and Therapy副主编;Cell and BioSciences副主编。在Nature (2)、Science、Nature Review Drug Discovery、Immunity (3)、Nature Immunology (2)、Nature Medicine (3)、Cell Stem Cell (5)、Cell Metabolism 、Nature Reviews Nephrology、PNAS (2)等国际知名学术期刊发表SCI收录的研究论文200余篇,所发表文章的他引24300余次,h-index 71,并先后获得中国侨界贡献奖创新人才奖等多项奖, 中国细胞学会干细胞成果转化奖等。


Dr. Yufang Shi received his Ph.D. in Immunology from the University of Alberta. He held a University Professor title at Robert Wood Johnson Medical School, Rutgers University and was a faculty member at the American Red Cross Holland Laboratory, and George Washington University. Since 2008, Dr. Shi has been working in his home country first as the director of the Institute of Health Sciences of Chinese Academy of Sciences and now the director of Soochow University Institutes for Translational Medicine.  

Dr. Shi has been studying apoptosis, especially in T cells since 1988. His findings on activation-induced cell death (AICD), role of c-myc in apoptosis, opioid and stress-induce lymphocyte apoptosis, mTOR inhibitor and cancer therapy, CD4 + T cells and asthma, granzyme B and Th2 AICD, and MHCIb CD8 + T cells and autoimmunity are well-recognized. His laboratory is now focusing on immune modulation and tissue repair by mesenchymal stem cells (MSCs). Based on their licensing concept of inflammation on MSC for immunosuppression, his lab determined the influence of varied amounts and kinds of inflammatory cytokines on the immunosuppression of MSCs and established the "cell empowerment" model for MSC-based therapy and the concept of the plasticity of MSC in immunomodulation. Recent studies from his group have shown that (1) The plasticity of MSC in immunomodulation is decided by the presence of different amounts and kinds of inflammatory cytokines which are in dynamic changes during the initiation and progression of inflammatory diseases; (2) Distinct key factor, nitric oxide (in mouse, rat, rabbit) or indoleamine-pyrrole 2,3-dioxygenase (in human, monkey, swine) mediates the immunosuppression of mesenchymal stem cells derived from various species; (3) MSC exhibit immunomodulatory activities in various immune disorders, including liver injury, restraint stress, and tumors. Dr. Shi’s more than 200 publications has appeared in Nature, Science, Nature Medicine, Nature Immunology Cell Stem Cell, Immunity, J. Exp. Med and other journals with more than 22,600 citations.

Dr. Shi is an Associate Editor of Oncogene, a Receiving Editor of Cell Death & Differentiation and an Editor-in-Chief of Cell Death and Diseases. He is an Associate Editor of Stem Cell Research and Therapy, Cellular Immunology, and Cell & Biosciences. He is currently on the editorial boards of Journal of Biological Chemistry, Cellular and Molecular Immunology, Journal of Molecular Cell Biology, and American Journal of Translational Research.



邀请函

下载邀请函
×
留下姓名电话和邮箱,邀请函直接发送到邮箱
*姓名:
* 电话:
* Email: